Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

PURPOSE: Current therapy for lung cancer involves multimodality therapies. However, many patients are either refractory to therapy or develop drug resistance. KRAS and epidermal growth factor receptor (EGFR) mutations represent some of the most common mutations in lung cancer, and many studies have...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Girnun, Geoffrey D., Chen, Liang, Silvaggi, Jessica, Drapkin, Ronny, Chirieac, Lucian R., Padera, Robert F., Upadhyay, Rabi, Vafai, Scott B., Weissleder, Ralph, Mahmood, Umar, Naseri, Elnaz, Buckley, Stephanie, Li, Danan, Force, Jeremy, McNamara, Kate, Demetri, George, Spiegelman, Bruce M., Wong, Kwok-Kin
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2008
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2696122/
https://ncbi.nlm.nih.gov/pubmed/18927287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-1128
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk